1. Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther. 2009; 1 (2): 1. [
DOI:10.4172/1948-5956.100000e2]
2. James V Lacey Jr , Susan S Devesa, Brinton LA. Environ Mol Mutagen. Environmental molecular mutagenesis. 2002; 39 (2‐3): 82-8. [
DOI:10.1002/em.10062]
3. Tahergorabi Z, Moodi M, Mesbahzadeh B. Breast Cancer: A preventable disease. J Birjand Univ Med Sci. 2014; 21 (2): 126-41.
4. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta Mol Basis Dis. 2008; 1782 (3): 127-50. [
DOI:10.1016/j.bbadis.2007.12.005]
5. Okamoto H. History of discoveries and pathogenicity of TT viruses. Curr Top Microbiol Immunol. 2009; 331: 1-20. [
DOI:10.1007/978-3-540-70972-5_1]
6. Zhong S, Yeo W, Tang M, Liu C, Lin Xr, Ho WM, et al. Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. J Med Virol. 2002; 66 (3): 428-34. [
DOI:10.1002/jmv.2163]
7. Jarkasi NS, Sekawi Z, Kqueen CY, Othman Z. PJSRR. Pertanika Journal of Scholarly Research Reviews. 2018; 4 (1).
8. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009; 227 (1): 75-86. [
DOI:10.1111/j.1600-065X.2008.00737.x]
9. Hennessy EJ, Parker AE, O'neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010; 9 (4): 293-307. [
DOI:10.1038/nrd3203]
10. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci. 1998; 95 (2): 588-93. [
DOI:10.1073/pnas.95.2.588]
11. Wujcicka W, Paradowska E, Studzińska M, Wilczyński J, Nowakowska D. Toll-like receptors genes polymorphisms and the occurrence of HCMV infection among pregnant women. Virol J. 2017; 14 (1): 64. [
DOI:10.1186/s12985-017-0730-8]
12. Noreen M, Arshad M. Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. Immunol Res. 2015; 62 (2): 234-52. [
DOI:10.1007/s12026-015-8640-6]
13. Żukowski M, Taryma-Leśniak O, Kaczmarczyk M, Kotfis K, Szydłowski Ł, Ciechanowicz A, et al. Relationship between toll-like receptor 2 R753Q and T16934A polymorphisms and Staphylococcus aureus nasal carriage. Anaesthesiol Intensive Ther. 2017; 49 (2): 110-5. [
DOI:10.5603/AIT.a2017.0027]
14. Manzin A, Mallus F, Macera L, Maggi F, Blois S. Global impact of Torque teno virus infection in wild and domesticated animals. J Infect Dev Ctries. 2015; 9 (06): 562-70. [
DOI:10.3855/jidc.6912]
15. Spandole-Dinu S, Cimponeriu DG, Crăciun A-M, Radu I, Nica S, Toma M, et al. Prevalence of human anelloviruses in Romanian healthy subjects and patients with common pathologies. BMC Infect Dis. 2018; 18 (1): 334. [
DOI:10.1186/s12879-018-3248-9]
16. Cimponeriu D, Ion DA, Spandole S, Apostol P, Toma M, Radu I, et al. Potential implication of genetic polymorphisms and Torque teno virus in sporadic breast cancer. Rom Biotechnol Lett. 2013; 18 (1): 7889.
17. de Villiers E-M, Schmidt R, Delius H, zur Hausen H. Heterogeneity of TT virus related sequences isolated from human tumour biopsy specimens. J Mol Med. 2002; 80 (1): 44-50. [
DOI:10.1007/s001090100281]
18. Tokita H, Murai S, Kamitsukasa H, Yagura M, Harada H, Takahashi M, et al. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus‐related chronic liver disease. J Med Virol. 2002; 67 (4): 501-9. [
DOI:10.1002/jmv.10129]
19. Zur Hausen H, de Villiers EM. Virus target cell conditioning model to explain some epidemiologic characteristics of childhood leukemias and lymphomas. Int J Cancer. 2005; 115 (1): 1-5. [
DOI:10.1002/ijc.20905]
20. Spandole S, Cimponeriu D, Berca LM, Mihăescu G. Human anelloviruses: an update of molecular, epidemiological and clinical aspects. Arch Virol. 2015; 160 (4): 893-908. [
DOI:10.1007/s00705-015-2363-9]
21. Figueiredo CP, Franz-Vasconcelos HC, Di Giunta G, Mazzuco TL, Caon T, Fernandes AL, et al. Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma. Leuk Lymphoma. 2007;48 (4): 731-5. [
DOI:10.1080/10428190701203954]
22. Bando M, Takahashi M, Ohno S, Hosono T, Hironaka M, Okamoto H, et al. Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer. Respirology. 2008; 13 (2): 263-9. [
DOI:10.1111/j.1440-1843.2007.01217.x]
23. Zheng H, Ye L, Fang X, Li B, Wang Y, Xiang X, et al. Torque teno virus (SANBAN Isolate) ORF2 protein suppresses NF-κB pathways via interaction with IκB kinases. J Virol. 2007; 81 (21): 11917-24. [
DOI:10.1128/JVI.01101-07]
24. Kincaid RP, Burke JM, Cox JC, de Villiers E-M, Sullivan CS. A human torque teno virus encodes a microRNA that inhibits interferon signaling. PLoS Pathog. 2013; 9 (12): e1003818. [
DOI:10.1371/journal.ppat.1003818]
25. Noreen M, Arshad M. Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. Immunol Res. 2015; 62 (2): 234-52. [
DOI:10.1007/s12026-015-8640-6]
26. Kutikhin AG, Yuzhalin AE. Genomics of pattern recognition receptors: Applications in oncology and cardiovascular diseases: Springer Science & Business Media; 2013. [
DOI:10.1007/978-3-0348-0688-6]
27. Kına I, Sultuybek GK, Soydas T, Yenmis G, Biceroglu H, Dirican A, et al. Variations in Toll-like receptor and nuclear factor-kappa B genes and the risk of glioma. Br J Neurosurg. 2018; 33: 165-70. [
DOI:10.1080/02688697.2018.1540764]
28. Wang X-Q, Liu L, Liu Y, Zhang K. TLR-2 gene polymorphisms and susceptibility to cancer: evidence from meta-analysis. Genet Test Mol Biomark. 2013; 17 (12): 864-72. [
DOI:10.1089/gtmb.2013.0246]
29. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC cancer. 2010; 10 (1): 382. [
DOI:10.1186/1471-2407-10-382]
30. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, et al. The toll‐like receptor 2 (TLR2)‐196 to‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer. 2012; 130 (6): 1470-5. [
DOI:10.1002/ijc.26143]
31. Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, et al. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. The Breast. 2012; 21 (4): 534-8. [
DOI:10.1016/j.breast.2012.04.001]
32. Hosseini SV, Mojtahedi Z, Beizavi Z, Khazraei H, Zamani M. Relationship between Arg753Gln Toll-like receptor 2 and Asp299Gly Toll-like receptor 4 genetic variations and susceptibility to colorectal cancer in southern Iran. Arch Biol Sci. 2018; 70 (4): 775-9. [
DOI:10.2298/ABS180812043H]
33. Semlali A, Alnemari R, Almalki E, Alrashed R, Alanazi M. Toll-Like Receptors Gene Polymorphism and Susceptibility to Cancer Development. Genetic Diversity and Disease Susceptibility: IntechOpen; 2018. [
DOI:10.5772/intechopen.78029]
34. Teng S, Madej T, Panchenko A, Alexov E. Modeling effects of human single nucleotide polymorphisms on protein-protein interactions. Biophys J. 2009; 96 (6): 2178-88. [
DOI:10.1016/j.bpj.2008.12.3904]
35. Takahashi K, Hoshino H, Ohta Y, Yoshida N, Mishiro S. Very high prevalence of TT virus (TTV) infection in general population of Japan revealed by a new set of PCR primers. Hepatol Res. 1998; 12 (3): 233-9. [
DOI:10.1016/S1386-6346(98)00068-0]